Elsey, Justin’s team published research in Scientific Reports in 2019 | CAS: 51364-51-3

Tris(dibenzylideneacetone)dipalladium(0)(cas: 51364-51-3) is used in the preparation of semiconducting polymers processed from nonchlorinated solvents into high performance thin film transistors.Quality Control of Tris(dibenzylideneacetone)dipalladium(0)It is used as catalyst for the synthesis of epoxides, alpha-arylation of ketones, in combination with BINAP for the asymmetric heck arylation of olefins, site-selective benzylic sp3 palladium-catalyzed direct arylation and homoallylic diamination of terminal olefins.

The author of 《Palladium based nanoparticles for the treatment of advanced melanoma》 were Elsey, Justin; Bubley, Jeffrey A.; Zhu, Lei; Rao, Shikha; Sasaki, Maiko; Pollack, Brian P.; Yang, Lily; Arbiser, Jack L.. And the article was published in Scientific Reports in 2019. Quality Control of Tris(dibenzylideneacetone)dipalladium(0) The author mentioned the following in the article:

IGF1R and CD44 are overexpressed in most advanced melanomas so we designed chemotherapeutic nanoparticles to target those receptors. Tris(dibenzylideneacetone)dipalladium (Tris DBA-Pd) is a novel inhibitor of N-myristoyltransferase 1 (NMT-1) and has proven in vivo activity against melanoma. However, poor solubility impairs its effectiveness. To improve its therapeutic efficacy and overcome drug resistance in advanced melanomas, we synthesized Tris DBA-Pd hyaluronic acid nanoparticles (Tris DBA-Pd HANP) and evaluated them against in vivo xenografts of LM36R, an aggressive BRAF mutant human melanoma resistant to BRAF inhibitors. We treated xenografted mice in four arms: empty HANPs, free Tris DBA-Pd, Tris DBA-Pd HANPs, and Tris DBA-Pd HANPs with IGF1R antibody. The Tris DBA-Pd HANP group was the most responsive to treatment and showed the greatest depletion of CD44-pos. cells on IHC. Surprisingly, the HANP containing IGF1R antibody was less effective than particles without antibody, possibly due to steric hindrance of IGF1R and CD44 binding. Tris DBA-Pd nanoparticles are an effective therapy for CD44-pos. tumors like melanoma, and further development of these nanoparticles should be pursued. In the experiment, the researchers used many compounds, for example, Tris(dibenzylideneacetone)dipalladium(0)(cas: 51364-51-3Quality Control of Tris(dibenzylideneacetone)dipalladium(0))

Tris(dibenzylideneacetone)dipalladium(0)(cas: 51364-51-3) is used in the preparation of semiconducting polymers processed from nonchlorinated solvents into high performance thin film transistors.Quality Control of Tris(dibenzylideneacetone)dipalladium(0)It is used as catalyst for the synthesis of epoxides, alpha-arylation of ketones, in combination with BINAP for the asymmetric heck arylation of olefins, site-selective benzylic sp3 palladium-catalyzed direct arylation and homoallylic diamination of terminal olefins.

Referemce:
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI